BRPI0715609A2 - COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION - Google Patents
COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- BRPI0715609A2 BRPI0715609A2 BRPI0715609-0A2A BRPI0715609A BRPI0715609A2 BR PI0715609 A2 BRPI0715609 A2 BR PI0715609A2 BR PI0715609 A BRPI0715609 A BR PI0715609A BR PI0715609 A2 BRPI0715609 A2 BR PI0715609A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- blood animal
- hot blood
- produce
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008280 blood Substances 0.000 title abstract 4
- 210000004369 blood Anatomy 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000038030 PI3Ks Human genes 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSTO, USO DE UM COMPOSTO,MÉTODO PARA PRODUZIR UM EFEITO ANTIPROLIFERATIVO EM UM ANIMAL DE SANGUE QUENTE, E PARA TRATAR UMA DOENÇA EM UM ANIMAL DE SANGUE QUENTE, E, COMPOSIÇÃO FARMACÊUTICA. É descrito um composto da fórmula (1) ou um sal farmaceuticamente aceitável deste, processos para sua preparação, composições farmacêuticas contendo-os e seu uso em terapia, por exemplo, particularmente no tratamento de doença proliferativa, tal como câncer, e particulamente em doença mediada por um mTOR quinase e/ou uma ou mais enzimas PI3K. COMPOUND, USE OF A COMPOUND, METHOD TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION. A compound of formula (1) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example, particularly in the treatment of proliferative disease, such as cancer, and particularly in disease, are described. mediated by an mTOR kinase and / or one or more PI3K enzymes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0616747A GB0616747D0 (en) | 2006-08-24 | 2006-08-24 | Novel compounds |
| US94854407P | 2007-07-09 | 2007-07-09 | |
| PCT/GB2007/003173 WO2008023159A1 (en) | 2006-08-24 | 2007-08-21 | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0715609A2 true BRPI0715609A2 (en) | 2013-10-08 |
Family
ID=37102735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0715609-0A2A BRPI0715609A2 (en) | 2006-08-24 | 2007-08-21 | COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION |
Country Status (7)
| Country | Link |
|---|---|
| CN (2) | CN101541781B (en) |
| BR (1) | BRPI0715609A2 (en) |
| ES (1) | ES2393215T3 (en) |
| GB (1) | GB0616747D0 (en) |
| RU (1) | RU2440349C2 (en) |
| TW (1) | TW200817384A (en) |
| ZA (1) | ZA200901015B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008023161A1 (en) * | 2006-08-23 | 2008-02-28 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| EP2519102B1 (en) * | 2009-12-28 | 2016-10-19 | Development Center For Biotechnology | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS |
| US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| WO2012148548A1 (en) * | 2011-02-25 | 2012-11-01 | Takeda Pharmaceutical Company Limited | N-substituted oxazinopteridines and oxazinopteridinones |
| CA2849189A1 (en) * | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| DK2855448T3 (en) | 2012-05-15 | 2017-05-01 | Cancer Res Tech Ltd | 5 - [[4 - [[MORPHOLIN-2-YL] METHYLAMINO] -5- (TRIFLUORMETHYL) -2-PYRIDYL] AMINO] PYRAZINE-2-CARBONITRIL AND THERAPEUTIC APPLICATIONS THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (en) * | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
| CN1186324C (en) * | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | Fused Heteroaryl Derivatives |
| JP2004524279A (en) * | 2000-11-10 | 2004-08-12 | エフ．ホフマン−ラ ロシュ アーゲー | Pyrimidine derivatives and their use as neuropeptide Y receptor ligands |
| US7423148B2 (en) * | 2002-11-21 | 2008-09-09 | Chiron Corporation | Small molecule PI 3-kinase inhibitors and methods of their use |
| GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415367D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| US7696202B2 (en) * | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
-
2006
- 2006-08-24 GB GB0616747A patent/GB0616747D0/en not_active Ceased
-
2007
- 2007-08-21 TW TW96130916A patent/TW200817384A/en unknown
- 2007-08-21 CN CN200780039262.7A patent/CN101541781B/en not_active Expired - Fee Related
- 2007-08-21 RU RU2009110255/04A patent/RU2440349C2/en not_active IP Right Cessation
- 2007-08-21 ES ES07789273T patent/ES2393215T3/en active Active
- 2007-08-21 BR BRPI0715609-0A2A patent/BRPI0715609A2/en not_active IP Right Cessation
- 2007-08-22 CN CNA2007800392665A patent/CN101558046A/en active Pending
-
2009
- 2009-02-12 ZA ZA200901015A patent/ZA200901015B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2440349C2 (en) | 2012-01-20 |
| ES2393215T3 (en) | 2012-12-19 |
| CN101558046A (en) | 2009-10-14 |
| CN101541781B (en) | 2014-01-08 |
| ZA200901015B (en) | 2010-08-25 |
| RU2009110255A (en) | 2010-09-27 |
| GB0616747D0 (en) | 2006-10-04 |
| CN101541781A (en) | 2009-09-23 |
| TW200817384A (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6390066A2 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| DOP2010000012A (en) | PYRIMIDINE MORFOLINE DERIVATIVES USED IN DISEASES RELATED TO MTOR QUINASA AND / OR PI3K | |
| UY30559A1 (en) | DERIVATIVES OF MORFOLINO PIRIMIDINA, PREPARATION PROCESSES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| BRPI0517634A (en) | thiazole derivative or a pharmaceutically acceptable derivative thereof, process for preparing a compound, pharmaceutical composition, use of a compound or pharmaceutically acceptable salt thereof, and method of treating a disease or condition | |
| ATE557015T1 (en) | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | |
| MX2009006613A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. | |
| BR112014029851A2 (en) | compound, inhibitors of ros1 kinase and ntrk kinase enzyme activity, pharmaceutical composition, antitumor agent, therapeutic agent for a tumor, method for treating a tumor, and, agent for treating a tumor | |
| BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| EA200970595A1 (en) | DERIVATIVES OF SUBSTITUTED INDAZOLS ACTIVE AS KINAZ INHIBITORS | |
| WO2009007751A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| EA201070167A1 (en) | SUBSTITUTED DERIVATIVES INDAZOLA, ACTIVE AS KINASE INHIBITORS | |
| MX2008012422A (en) | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors. | |
| ATE514699T1 (en) | SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVES AS KINASE INHIBITORS | |
| BRPI0805826A2 (en) | spiro-substituted compounds as angiogenesis inhibitors, compound production method, pharmaceutical composition and treatment methods | |
| BR112015029512A2 (en) | pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
| BRPI0622054B8 (en) | compound and pharmaceutical composition | |
| BRPI0912411B8 (en) | use of a human interleukin-2 mutein (hil-2 mutein) and pharmaceutical composition for the treatment and/or prophylaxis of an autoimmune disease | |
| BRPI0512796A (en) | compound, process for preparing same, pharmaceutical composition, use of a compound, and methods for producing an inhibitory effect of b-raf, and an anticancer effect on a warm-blooded animal, and for treating a disease. | |
| BR112015029401A8 (en) | pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination | |
| BRPI0715609A2 (en) | COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION | |
| BRPI0513513A (en) | compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an eg5 inhibitory effect and an anticancer effect on a warm-blooded animal , and to treat carcinomas in a warm-blooded animal | |
| BR112019018615A2 (en) | antimicrobial compounds, compositions and uses thereof | |
| UA102219C2 (en) | Substotuted pyrazolo-quinazoline derivatives, process for the preparation and use thereof as kinase inhibitors | |
| BR112012020377A8 (en) | use of one or more selected from the group consisting of a compound of formula (i), a racemic-diastereomeric mixture and an optical isomer of said compound, and a pharmaceutically acceptable salt and prodrug thereof, method, pharmaceutical composition and treatment kit cachexia and commercial packaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |